<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=1400074&amp;fmt=gif">

Lung Nodule Diagnosis


nodifylung-654

Nodify Lung™ consists of two blood-based proteomic tests (the Nodify CDT™ & Nodify XL2® tests) to help physicians reclassify risk of cancer and aid in stratifying patients into distinct nodule management pathways: intervention or surveillance.

ORDER NODIFY LUNG TESTING

One simple blood draw. Two ways to help decipher the risk of malignancy of a lung nodule.

nodify-cdt-line-540-risk

Helps identify patients who may benefit from timely intervention with results in one day.

LEARN MORE ABOUT THE NODIFY CDT TEST

 

nodify-xl2-line-540-risk

Helps identify patients who may benefit from computed tomography (CT) surveillance with results in one week.

LEARN MORE ABOUT THE NODIFY XL2 Test

Watch our Nodify Lung informational video series to learn more about our cohesive testing strategy for nodule management

Which patients are eligible for Nodify Lung testing?

Order Nodify Testing

Nodify Lung testing is intended for patients with incidental lung nodules:​

  • R91.1 (solitary nodule) or R91.8 (multiple nodules) ICD-10 code​
  • ≥40 years old​
  • 8-30 mm nodule​
  • ≤65% risk of malignancy (Solitary Pulmonary Nodule calculator (Mayo Model)1)​
  • No previous diagnosis of cancer ​
    Patients are eligible for Nodify XL2 testing if history of non-lung cancer is >5 years and risk of malignancy is ≤50%

There is no out of pocket expense for Medicaid or covered Medicare patients for Nodify Lung testing

Learn more about our reimbursement

Interested in ordering Nodify Lung testing?

The Nodify Lung Blood Specimen Collection Kit is used for both the Nodify CDT and the Nodify XL2 proteomic tests.

DOWNLOAD OUR INFORMATIONAL BROCHURE
ORDER NODIFY LUNG TESTING
CONTACT OUR TEAM

Get in touch

Contact Us

Data library

Discover More
  1. Gould M, Donington J, Lynch W, et al. Evaluation of Individuals with Pulmonary Nodules: When is it Lung Cancer? CHEST. 2013; 143(5): e93S-e120S.

* According to the ACCP guidelines, patients with a Very Low risk of malignancy should be considered for CT surveillance and patients with a High risk should receive a stage evaluation and appropriate intervention.